Girard Partners’s Bristol-Myers Squibb BMY Stock Holding History

Girard Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1.08M	Sell	26,013 -2,592	-9%	-$116K	0.1%	134
2024 Q1	$1.55M	Sell	28,605 -1,963	-6%	-$100K	0.15%	117
2023 Q4	$1.57M	Sell	30,568 -2,859	-9%	-$150K	0.16%	116
2023 Q3	$1.94M	Buy	33,427 +1,478	+5%	+$90.6K	0.22%	99
2023 Q2	$2.04M	Buy	31,949 +3,253	+11%	+$218K	0.22%	94
2023 Q1	$1.99M	Sell	28,696 -1,674	-6%	-$118K	0.22%	92
2022 Q4	$2.19M	Buy	30,370 +1,944	+7%	+$147K	0.25%	94
2022 Q3	$2.02M	Sell	28,426 -182	-0.6%	-$13.2K	0.27%	82
2022 Q2	$2.2M	Buy	28,608 +24,760	+643%	+$1.89M	0.28%	88
2022 Q1	$281K	Sell	3,848 -171	-4%	-$11.5K	0.03%	199
2021 Q4	$250K	Sell	4,019 -184	-4%	-$10.8K	0.03%	211
2021 Q3	$248K	Sell	4,203 -341	-8%	-$22.5K	0.03%	207
2021 Q2	$303K	Sell	4,544 -667	-13%	-$43.5K	0.04%	199
2021 Q1	$329K	Sell	5,211 -1,721	-25%	-$107K	0.05%	179
2020 Q4	$429K	Sell	6,932 -1,191	-15%	-$73.2K	0.07%	160
2020 Q3	$489K	Sell	8,123 -2,744	-25%	-$165K	0.08%	145
2020 Q2	$639K	Sell	10,867 -4,251	-28%	-$254K	0.12%	125
2020 Q1	$842K	Sell	15,118 -6,944	-31%	-$424K	0.17%	111
2019 Q4	$1.42M	Buy	22,062 +8,205	+59%	+$470K	0.23%	104
2019 Q3	$702K	Sell	13,857 -9,582	-41%	-$450K	0.13%	127
2019 Q2	$1.06M	Buy	23,439 +4,090	+21%	+$191K	0.19%	109
2019 Q1	$923K	Sell	19,349 -207	-1%	-$10.3K	0.17%	119
2018 Q4	$1.02M	Sell	19,556 -2,267	-10%	-$122K	0.21%	103
2018 Q3	$1.35M	Sell	21,823 -5,595	-20%	-$332K	0.24%	101
2018 Q2	$1.52M	Sell	27,418 -1,129	-4%	-$61K	0.29%	92
2018 Q1	$1.81M	Sell	28,547 -748	-3%	-$48.1K	0.42%	67
2017 Q4	$1.79M	Sell	29,295 -809	-3%	-$50.6K	0.34%	81
2017 Q3	$1.92M	Sell	30,104 -2,459	-8%	-$144K	0.4%	75
2017 Q2	$1.81M	Sell	32,563 -3,010	-8%	-$164K	0.39%	74
2017 Q1	$1.93M	Sell	35,573 -124	-0.3%	-$6.8K	0.47%	73
2016 Q4	$2.09M	Buy	35,697 +883	+3%	+$48.3K	0.61%	58
2016 Q3	$1.88M	Buy	34,814 +6,356	+22%	+$408K	0.62%	60
2016 Q2	$2.09M	Buy	28,458 +9,362	+49%	+$662K	0.8%	46
2016 Q1	$1.22M	Sell	19,096 -714	-4%	-$45K	0.53%	60
2015 Q4	$1.36M	Buy	19,810 +2,672	+16%	+$177K	0.66%	52
2015 Q3	$1.01M	Buy	17,138 +144	+0.8%	+$9.13K	0.58%	61
2015 Q2	$1.13M	Buy	16,994 +3,874	+30%	+$255K	0.63%	54
2015 Q1	$846K	Buy	13,120 +460	+4%	+$28.8K	0.5%	68
2014 Q4	$747K	Buy	12,660 +564	+5%	+$31.8K	0.47%	66
2014 Q3	$619K	Buy	12,096 +1,100	+10%	+$54.9K	0.41%	73
2014 Q2	$533K	Buy	10,996 +1,828	+20%	+$90.1K	0.37%	77
2014 Q1	$476K	Buy	9,168 +2,308	+34%	+$123K	0.34%	79
2013 Q4	$365K	Buy	+6,860	New	+$349K	0.29%	79

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Girard Partners's BMY Position: Q2 2024 in Review

Girard Partners reduced its Bristol-Myers Squibb (BMY) stake by 9.1% in Q2 2024, selling an estimated $116K and leaving 26,013 shares worth $1.08M. The position accounts for 0.1% of the portfolio, ranked #134.

Girard Partners first reported a position in BMY in Q4 2013 and has held it in 43 quarters since. The position peaked at $2.2M in Q2 2022. 2,147 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Girard Partners held 26,013 shares of Bristol-Myers Squibb worth $1.08M as of Q2 2024.
Girard Partners sold 2,592 Bristol-Myers Squibb shares in Q2 2024, an estimated $116K.
Bristol-Myers Squibb made up 0.1% of Girard Partners's portfolio in Q2 2024, its #134 holding.
Girard Partners first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 43 quarters since.
Girard Partners's Bristol-Myers Squibb position peaked at $2.2M in Q2 2022.
2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Girard Partners's 13F filing for Q2 2024, filed 12 Aug 2024.